Royal Bank Of Canada Finch Therapeutics Group, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.75 - $51.3 $280 - $8,208	160 New	160 $0
Q2 2022 Aug 15, 2022	SELL	$1.91 - $5.11 $888 - $2,376	-465 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.02 - $10.47 $5,918 - $12,344	-1,179 Reduced 71.72%	465 $2,000
Q4 2021 Feb 14, 2022	BUY	$8.95 - $16.88 $7,750 - $14,618	866 Added 111.31%	1,644 $16,000
Q3 2021 Nov 15, 2021	BUY	$12.2 - $16.75 $3,159 - $4,338	259 Added 49.9%	778 $10,000
Q2 2021 Aug 16, 2021	BUY	$12.03 - $17.51 $6,243 - $9,087	519 New	519 $7,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $575M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.